Showing results (81-90 of 208) with videos related to
Sort By:
Pageof 21
European Journal of Cancer (Oxford, England : 1990)|July 31, 2017
Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017Selma Ugurel, Joachim Röhmel, Paolo A Ascierto, et al.Journal of the American Academy of Dermatology|July 19, 2021
Molecular characterization of fast-growing melanomasCaroline Gaudy-Marqueste, Nicolas Macagno, Anderson Loundou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 2020
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629)Jean-Jacques Grob, Rene Gonzalez, Nicole Basset-Seguin, et al.Journal of Translational Medicine|April 8, 2021
The "Great Debate" at Melanoma Bridge 2020: December, 5th, 2020Paolo A Ascierto, Michael B Atkins, Alexander M Eggermont, et al.Journal for Immunotherapy of Cancer|July 24, 2021
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II studySandra P D'Angelo, Celeste Lebbé, Laurent Mortier, et al.Cancer|March 29, 2014
A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanomaOmid Hamid, Robert Ilaria, Claus Garbe, et al.European Journal of Cancer (Oxford, England : 1990)|May 11, 2023
Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trialDirk Schadendorf, Hussein Tawbi, Evan J Lipson, et al.JAMA Oncology|June 30, 2017
Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical TrialsGeorgina V Long, Jeffrey S Weber, James Larkin, et al.The Lancet. Oncology|December 17, 2009
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyJedd D Wolchok, Bart Neyns, Gerald Linette, et al.Dermatology and Therapy|September 24, 2021
Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629Brett G M Hughes, Rene Gonzalez Mendoza, Nicole Basset-Seguin, et al.Pageof 21